Skip to Main Content

Paper Details

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
Blood
20
2014
ABL1, BCR, CK-), CML, CML cell lines, Cdk, T187A, chronic myeloid leukemia, cyclin-dependent kinase, cytoplasm, cytoplasmic oncogene, cytoplasmic p27, leukemia, leukemogenesis, murine, normal cells, nuclear p27, nuclear tumor suppressor, p27, p27 mutant, p27(, tumor, tyrosine, tyrosine kinase
Animals, Cell Transformation, Neoplastic, Cells, Cultured, Cyclin-Dependent Kinase Inhibitor p27, Cytoplasm, Fusion Proteins, bcr-abl, Genes, Tumor Suppressor, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Mice, Inbred C57BL, Mice, Transgenic, Oncogene Proteins, Protein Transport
Author NameAffiliation
Anupriya AgarwalKnight Cancer Institute, Oregon Health & Science University
Ryan J MackenzieKnight Cancer Institute, Oregon Health & Science University
Arnaud BessonCancer Research Center of Toulouse, INSERM Unite Mixte de Recherche 7, Universite de Toulouse
Sophia JengKnight Cancer Institute.
Alyssa CareyKnight Cancer Institute, Oregon Health & Science University
Dorian LaTochaKnight Cancer Institute, Oregon Health & Science University
Angela G FleischmanKnight Cancer Institute, Oregon Health & Science University
Nicolas DuquesnesCancer Research Center of Toulouse, INSERM Unite Mixte de Recherche 7, Universite de Toulouse
Christopher A EideKnight Cancer Institute, Oregon Health & Science University, OR Howard Hughes Medical Institute
Kavin B VasudevanKnight Cancer Institute, Oregon Health & Science University
Marc M LoriauxKnight Cancer Institute, Oregon Health & Science University
Eduardo FirpoFred Hutchinson Cancer Research Center
Jorge CortesThe University of Texas MD Anderson Cancer Center
Shannon K McWeeneyKnight Cancer Institute.
Thomas O'HareDivision of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, The University of Utah
James M RobertsFred Hutchinson Cancer Research Center
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, OR Howard Hughes Medical Institute
Michael W DeiningerDivision of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, The University of Utah
  • 1 - 18

Datasets

Release 1.2